Lepu Biopharma develops monoclonal antibodies and antibody-drug conjugates (ADCs) targeting oncology to provide effective treatments for cancer patients facing unmet medical needs. The company combines in-house research and development with strategic collaborations to create a differentiated product pipeline and enhance manufacturing capabilities.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer patients often face limited treatment options and unmet medical needs, necessitating the development of more effective and targeted therapies. The development of novel oncology drugs requires significant investment in research and development, as well as advanced manufacturing capabilities.
Solution
Lepu Biopharma is a biopharmaceutical company focused on developing innovative oncology therapeutics, including monoclonal antibodies and antibody-drug conjugates (ADCs). The company utilizes in-house research and development, combined with strategic collaborations, to create a differentiated product pipeline. Lepu Biopharma aims to address unmet medical needs in cancer treatment by developing first-in-class and best-in-class drugs, leveraging advanced technology platforms for antibody discovery, ADC development, and process optimization.
Target Audience
The primary target audience includes cancer patients with unmet medical needs, as well as healthcare providers and researchers in the field of oncology.
Features
- ADC technology platform for targeted drug delivery to cancer cells
- Antibody discovery platform for generating novel monoclonal antibodies
- Advanced process and analytical development platform for efficient manufacturing
- Pipeline of product candidates including monoclonal antibodies, ADCs, and oncolytic viruses
- GMP-compliant antibody production line with 2,000L capacity
- Oncolytic virus production line under construction
- Over 55 issued patents in multiple countries, including China, the U.S., Japan, and the European Union